187 related articles for article (PubMed ID: 33596162)
1. Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria.
Russo A; Berruti M; Giacobbe DR; Vena A; Bassetti M
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):983-991. PubMed ID: 33596162
[No Abstract] [Full Text] [Related]
2. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Bassetti M; Giacobbe DR; Robba C; Pelosi P; Vena A
Curr Opin Infect Dis; 2020 Dec; 33(6):474-481. PubMed ID: 33060469
[TBL] [Abstract][Full Text] [Related]
3. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
4. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
5. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Tamma PD; Rodriguez-Bano J
Clin Infect Dis; 2017 Apr; 64(7):972-980. PubMed ID: 28362938
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
7. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
Watkins RR; Deresinski S
Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
[No Abstract] [Full Text] [Related]
8. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
D'Angelo RG; Johnson JK; Bork JT; Heil EL
Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
[TBL] [Abstract][Full Text] [Related]
9. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
10. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Montravers P; Bassetti M
Curr Opin Infect Dis; 2018 Dec; 31(6):587-593. PubMed ID: 30299359
[TBL] [Abstract][Full Text] [Related]
11. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
12. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
13. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
14. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
15. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Gudiol C; Cuervo G; Carratalà J
Curr Opin Crit Care; 2019 Oct; 25(5):438-448. PubMed ID: 31369411
[TBL] [Abstract][Full Text] [Related]
16. Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Maseda E; Suárez de la Rica A
Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):41-45. PubMed ID: 36285857
[TBL] [Abstract][Full Text] [Related]
17. Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Bouxom H; Fournier D; Bouiller K; Hocquet D; Bertrand X
Int J Antimicrob Agents; 2018 Jul; 52(1):100-103. PubMed ID: 29580930
[TBL] [Abstract][Full Text] [Related]
18. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
19. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
